Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data

Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.

Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus

Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.

Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y

Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.

Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat

Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.

ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.

Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat

Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.

Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates

Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.

Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent

Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.

Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance

AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.

Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag

Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.

Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.

TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down

TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.

Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings

AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down

Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.

What's in the Cards for AbbVie (ABBV) This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates

J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Roche (RHHBY) Q1 Sales Affected by Biosimilars & COVID-19

Roche's (RHHBY) performance in the first quarter of 2021 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe

Sanofi's (SNY) new cancer drug, Sarclisa, gets second approval for treating multiple myeloma patients in Europe within a year.

Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.